PDCD1 and familial pancreatic carcinoma: To further validate whether Ccn1 deletion can enhances the efficacy of anti‐PD1 and gemcitabine in pancreatic cancer treatment, we established an orthotopic pancreatic tumor model in mice by inoculating KPC cells, followed by treatment with anti‐PD1 and gemcitabine.